Maraviroc: A CCR5-receptor antagonist for the treatment of HIV-1 infection

Clinical Therapeutics

Volumn 30, Issue 7, 2008, Pages 1228-1250

  Lieberman Blum, Sharon S ^a   Fung, Horatio B ^a   Bandres, Juan C ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

CCR5 receptor antagonist; entry inhibitor; HIV 1 infection; maraviroc

Indexed keywords

APLAVIROC; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR; EFAVIRENZ; ETRAVIRINE; KETOCONAZOLE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; PLACEBO; RALTEGRAVIR; RIFAMPICIN; RITONAVIR; SAQUINAVIR; VICRIVIROC;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; APPETITE DISORDER; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; BRONCHITIS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; COUGHING; DEMOGRAPHY; DIARRHEA; DIZZINESS; DRUG BINDING; DRUG CONFORMATION; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL PAIN; GINGIVITIS; HEADACHE; HERPES; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; INSOMNIA; LIFE EXPECTANCY; LIVER TOXICITY; MEDICAL INFORMATION; MEDLINE; MULTIDRUG RESISTANCE; MUSCULOSKELETAL DISEASE; NAUSEA; NEOPLASM; NEUTROPHIL COUNT; ORTHOSTATIC HYPOTENSION; PLASMA PROTEIN BINDING; PREDICTION; PUBLICATION; QUALITY OF LIFE; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SLEEP DISORDER; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; VIRUS LOAD;

ANTI-HIV AGENTS; CYCLOHEXANES; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; RECEPTORS, CCR5; TRIAZOLES;

EID: 48549106475     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(08)80048-3     Document Type: Article

References (63)

1. 2007 AIDS epidemic update [UNAIDS Web site].
2. (February 10, 2008). http://www.unaids.org/en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/2007default.asp Accessed
3. Gulick R.M. New antiretroviral drugs. Clin Microbiol Infect 9 (2003) 186-193
4. Hogg R.S., Bangsberg D.R., Lima V.D., et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med. 3 (2006) e356
5. Mocroft A., Ledergerber B., Viard J.P., et al., for the Euro-SIDA Study Group. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: Results from the EuroSIDA Study Group. J Infect Dis 190 (2004) 1947-1956
6. Nagashima K.A., Thompson D.A., Rosenfield S.I., et al. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 183 (2001) 1121-1125
7. Berger E.A., Doms R.W., Fenyö E.M., et al., for the HIV Network for Prevention Trials Vaccine Preparedness Protocol Team. A new classification for HIV-1. Nature 319 (1998) 240
8. Samson M., Libert F., Doranz B.J., et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382 (1996) 722-725
9. Liu R., Paxton W.A., Choe S., et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86 (1996) 367-377
10. Marmor M., Sheppard H.W., Donnell D., et al. Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection. J Acquir Immune Defic Syndr 27 (2001) 472-481
11. de Roda Husman A.M., Koot M., Cornelissen M., et al. Association between CCR5 genotype and the clinical course of HIV-11 infection. Ann Intern Med 127 (1997) 882-890
12. Wheeler J., McHale M., Jackson V., and Penny M. Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: Experience in a drug development programme for maraviroc. Antivir Ther 12 (2007) 233-245
13. Selzentry [package insert] (2007), Pfizer NY: Inc, New York
14. Moore J.P., and Doms R.W. The entry of entry inhibitors: A fusion of science and medicine. Proc Natl Acad Sci U S A 100 (2003) 10598-10602
15. Reeves J.D., Gallo S.A., Ahmad N., et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A 99 (2002) 16249-16254
16. Cooley L.A., and Lewin S.R. HIV-1 cell entry and advances in viral entry inhibitor therapy. J Clin Virol 26 (2003) 1121-1132
17. Cammack N. The potential for HIV fusion inhibition. Curr Opin Infect Dis 14 (2001) 13-16
18. Doms R.W., and Trono D. The plasma membrane as a combat zone in the HIV battlefield. Genes Dev 14 (2000) 2677-2688
19. Dorr P., Westby M., Dobbs S., et al. Maraviroc (UUK-427,857), a potent, orally bioavailable,and selective small-molecule inhibitor of chemokine receptor CCR5 with broadspectrum anti-human immunode-ficiency virus type 1 activity. Antimi-crob Agents Chemother 49 (2005) 4721-4732
20. Meanwell N.A., and Kadow J.F. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS. Curr Opin Investig Drugs 8 (2007) 669-681
21. Fätkenheuer G., Pozniak A.L., Johnson M.A., et al. Efficacy of shortterm monotherapy with maraviroc, a new CCR5 ntagonist, n patients infected with HIV-1. Nat Med 11 (2005) 1170-1172
22. Biswas P., Tambussi G., and Lazzarin A. Access denied? The status of coreceptor inhibition to counter HIV entry. Expert Opin Pharmacother 8 (2007) 923-933
23. Abel S., van der Ryst E., Rosario M.C., et al. Assessment of the pharmaco-kinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br J Clin Pharmacol 65 1 (2008) 5-18
24. Dumond JB, Patterson KB, Pecha A, et al. Maraviroc pharmacokinetics in blood plasma, genital tract fluid and tissue in healthy female volunteers. Presented at: 15th Conference on Retroviruses and Opportunistic Infections; Febreary 3-6, 2008; Boston, Mass. Abstract 135LB.
25. Lalezari J, Goodrich J, DeJesus E, et al, for the MOTIVATE 1 Study Team. Efficacy and safety of maraviroc in antiretroviral-experienced patients infected with CCR5-tropic HIV-1: 48-Weeks results of MOTIVATE-1 Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, Ill. Abstract 104bLB.
26. Fatkenheuer G, Konourina I, Nelson M, et al, for the MOTIVATE 2 Study Team. Efficacy and safety of maraviroc (MVC) plus optimized background therapy (OBT)in viraemic, antiretroviral treatment-experienced patients infected with CCR5-ttropic (R5)HIV-1 in Europe, Australia and North America (MMOTIVATE 2): 48-Week results. Presented at: 11th European Conference; October 24-27, 2007; Madrid, Spain. Abstract PS3/5.
27. Walker D.K., Abel S., Comby P., et al. Species differences in the disposition of the CCR5 antagonist, UK-4427,857, a new potential treatment for HIV. Drug Metab Dispos 33 (2005) 587-595
28. Maraviroc tablets NDA 22-128 [briefing document] [US Food and Drug Administration Web site].
29. (2008). http://wwww.fda.gov/ohrms/dockets/ac/007/briefing/2007-4283b1-01-Pfizer.pdf February 10, Accessed
30. Hoepelman IM, Ayoub A, Heera J, et al. The incidence of severe liver enzyme abnormalities and hepatic adverse events in the maraviroc clinical development programme. Presented at: 11th European AIDS Conference; 24-27, 2007; Madrid, Spain. Abstract LBP7.99/1.
31. Westby M., Smith-Burchnell C., Mori J., et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bbound receptor for entry. J Virol 81 (2007) 2359-2371
32. Naeger LK. Resistance and tropism-maraviroc.
33. (July 10, 2008). http://www.scribd.com/doc/1118185/US-Food-and-Drug-Administration-20074283s10204FDA-Naeger Accessed
34. McFadyen L, Jacqmin P, Wade JR, et al. Maraviroc (MVC) exposure-efficacy relationship in treatment-experienced HIV-1-infected patients. Presented at: 11th European Conference; October 24-27, 2007; Madrid, Spain. Abstract P4.1/06.
35. Saag M, Ive P, Heera J, et al. A multicenter, randomized, double-bblind, comparative trial of a novel CCR5 antagonist, maraviroc, versus efavirenz, both in combination with combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive subjects infected with R5 HIV-1: Week 48 results of the MERIT study. Presented at: 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Abstract WESS104.
36. van der Ryst E, Cooper D, Konourina I, et al. Efficacy of maraviroc in combination with at least one other potent new antiretroviral drug: 24-Week combined analysis of the MOTIVATE 1 and 2 studies. Presented at: 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Abstract WEPEB115LB.
37. Gulick RM, van der Ryst E, Lampiris H, et al. Efficacy and safety of once-daily (QD) compared with twicedaily (BID) maraviroc plus optimized background therapy (OBT) in treatment-experienced patients infected with CCR5-tropic HIV-1: 24-Week combined analysis of the MOTIVATE 1 and 2 studies. Presented at: 4th International AIDS Society Conference on HIV Pathogenesis, Prevention; July 22-25, 2007; Sydney, Australia. Abstract WEPEB116LB.
38. Hardy D, Reynes J, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in treatment-experienced patients infected with CCR5-ttropic HIV-1: 48-Week combined analysis of the MOTIVATE studies. Presented at: 15th Conference on Retroviruses Infections; February 3-6, 2008; Boston, Mass. Abstract 792.
39. Mayer H, van der Ryst E, Saag M, et al. Safety and efficacy of maraviroc, a novel CCR5 antagonist, when used in combination with optimized background therapy for the treatment of antiretroviral-experienced subjects infected with dual/mixed-tropic HIV-1: 24-Week results of a Phase 2b exploratory trial. Presented at: 16th International AIDS Conference; August 13-18, 2006; Toronto, Canada. Abstract TH HLB 0215.
40. Goodrich JM, Saag M, van der Ryst E, et al. 48-Week safety and efficacy of maraviroc, a novel CCR5 antagonist, in combination with optimized background therapy (OBT) for the treatment of antiretroviral-experienced patients infected with dual/mixed-tropic HIV-1. Presented at: 45th Annual Meeting of Infectious Diseases Society of America; October 4-7, 2007; Diego, Calif. Abstract LB-22.
41. McHale M, Abel S, Russell D, et al. Overview of Phase 1 and 2a safety and efficacy data of maraviroc (UK-427,857). Presented at: 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 24-27, 2005; Rio de Janeiro, Brazil. Abstract TuOa 0204.
42. Davis J.D., Hackman F., Layton G., et al. Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects. Br J Clin Pharmacol 65 Suppl 1 (2008) 68-75
43. Winston A., Mallon P.W., and Boffito M. The clinical pharmacology of antiretrovirals in development. Expert Opin Drug Metab Toxicol 2 (2006) 447-458
44. Abel S., Russell D., Taylor-Worth R.J., et al. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 65 Suppl 1 (2008) 27-37
45. Abel S, Ridgway C, Hamlin J, et al. An open, randomized, 2-way cross-over study to investigate the effect of darunavir/ritonavir on the pharmacokinetics of maraviroc in healthy subjects. Presented at: 16th International HIV Drug Resistance Workshop; July 12-16, 2007; Barbados, West Indies. Abstract 55.
46. Abel S., Jenkins T.M., Whitlock L.A., et al. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 65 Suppl 1 (2008) 38-46
47. Davis J, Scholler-GGyyre M, Kakuda TN, et al. An open, randomized, two-period, crossover study in two cohorts to investigate the effect of steady-state TMC125 (etravirine) and the combination of TMC125/darunavir/ritonavir on the steady-state pharmacokinetics of oral maraviroc in healthy subjects. Presented at: 11th European AIDS Conference; October 24-27, 2007; Madrid, Spain. Abstract P4.33/02.
48. Muirhead G, Pozniak A, Gazzard B, et al. A novel probe drug interaction study to investigate the effect of selected ARV combinations on the pharmacokinetics of a single oral dose of maraviroc (UK-427,857) in HIV +ve subjects. Presented at: 12th Conference on Retroviruses Infections; February 22-25, 2005; Boston, Mass. Abstract 663.
49. Abel S., Russell D., Whitlock L.A., et al. Effect of maraviroc on the pharmaco-kinetics of midazolam, lamivudine/ zidovudine, and ethinyloestradiol/ levonorgestrel in healthy volunteers. Br J Clin Pharmacol 65 Suppl 1 (2008) 19-26
50. Abel S., Russell D., Whitlock L.A., et al. The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers. BrJ Clin Pharmacol 65 Suppl 1 (2008) 47-53
51. 2008 Drug Topics Red Book (2008), Thomson Medical Economics, Montvale, NJ
52. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.
53. (2008). http://aidsinfo.nih.gov/contentfiles/AdultanclAdolescentGL.pdf February 10, Accessed
54. FAQs-physician questions [Trofile co-receptor tropism assay Web site]..
55. (2008). http://www.trofileassay.com/FAQs_Physician-Questions February 10, Accessed
56. Kuehne FC, Chancellor J, Mollon P, Powderly W. Modelling the costeffectiveness of maraviroc for anti retroviral treatment-experienced individuals. Presented at: 11th European AIDS Conference; October 24-27, 2007; Madrid, Spain. Abstract P10.4/02.
57. Westby M., Lewis M., Whitcomb J., et al. Emergence of CXCR4-using human immunodeficiencyvirus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 80 (2006) 4909-4920
58. Westby M., and van der Ryst E. CCR5 antagonists: Host-targeted antivirals for the treatment of HIV infec tion. Antivir Chem Chemother 16 (2005) 339-354
59. Lorenzen T., Stoehr A., Walther I., and Plettenberg A. CCR5 antagonists in the treatment of treatment-experi enced patients infected with CCR5 tropic HIV-1. Eur J Med Res 12 (2007) 419-425
60. van der Ryst E, Westby M. Changes in HIV-1 co-receptor tropism for patients participating in the maravi roc MOTIVATE 1 and 2 clinical trials. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 1720, 2007; Chicago, III. Abstract H715.
61. Reeves JD, Han D, Liu Y, et al. Enhancements to the Trofile HIV coreceptor tropism assay enable im proved detection of CXCR4-using subpopulations and earlier detection of CXCR4-using viruses in sequential patient samples. Presented at: 11th European AIDS Conference/ EACS; October 24-27, 2007; Madrid, Spain. Abstract P1.2/03.
62. Telenti A., and Egger M. Identifying safety concerns from genetic data: Lesions from the development of CCR5 inhibitors. AntivirTher 12 (2007) 147-148
63. Mueller M.C., and Bogner J.R. Treatment with CCR5 antagonists: Which patient may have a benefit?. Eur J Med Res 12 (2007) 441-452